News Release

July 24 2025

IQVIA Services Japan G.K. and Cancer Institute Hospital of JFCR launch strategic clinical trials partnership

IQVIA Services Japan G.K. (Head office: Minato-ku, Tokyo; President: Fumihiko Ugajin), a company of the IQVIA Japan Group, and the Cancer Institute Hospital of JFCR (Head office: Koto-ku, Tokyo; Hospital Director: Takeshi Sano) announced today that they have entered into a strategic partnership to promote cancer clinical trials and address Japan's so-called "drug loss" problem, which refers to the situation in which a drug is approved overseas but not in Japan.

IQVIA has built a robust global network of clinical trial sites through strategic partnerships with leading medical institutions across approximately 70 countries. This network includes around 50 Prime Sites, distinguished for their advanced capabilities and consistent high performance in conducting clinical trials, as well as approximately 1,100 Partner Sites, which serve as the foundational hubs of IQVIA's site operations within their respective regions.

By fostering close, collaborative relationships with these sites, IQVIA empowers them to adopt innovative approaches to clinical research. This partnership model enhances the efficiency and quality of trial execution while also expanding access for patients to participate in cutting-edge clinical studies.

The Cancer Institute Hospital of JFCR will join IQVIA's network of clinical sites as the first Prime Site in Japan. Both parties will aim to conduct clinical trials at the Cancer Institute Hospital of JFCR quickly and effectively by leveraging each other's expertise, knowledge and experience. Through this initiative, the Cancer Institute Hospital of JFCR aims to actively participate in a greater number of international collaborative clinical trials and make significant contributions to their progress. This is expected to accelerate the domestic approval of new drugs and ultimately contribute to resolving the issue of domestic drug loss.

Hideyasu Matsuda, VP, Clinical Development, at IQVIA Japan, said, "We are pleased that the Cancer Institute Hospital of JFCR will be IQVIA's first Prime Site in Japan. We have high hopes that by combining Cancer Institute Hospital of JFCR's nation-leading track record and high level of expertise in the field of oncology with IQVIA's cutting-edge global knowledge, pioneering use of technology and the expertise of its specialized oncology unit, we will be able to carry out clinical trials that are fully comparable to those of leading institutions worldwide. IQVIA would like to make the greatest possible contribution to working with Cancer Institute Hospital of JFCR to deliver new therapeutic drugs to patients who need them as soon as possible."

Takeshi Sano, Director of the Cancer Institute Hospital of JFCR, stated, "Currently, there are many drugs in the cancer field that have been approved overseas but have not been approved in Japan. By partnering with IQVIA, a major global CRO (clinical research organization), we hope to deepen our collaboration with overseas EBPs (emerging biopharmaceutical companies) that handle drugs that have not been approved in Japan and become even more involved in the development of next-generation new drugs.

“We hope that this partnership with IQVIA will help us realize the Cancer Institute's philosophy of contributing to the welfare of humanity by overcoming cancer."

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 88,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances in an effort to advance their path toward cures. To learn more, visit www.iqvia.com. For the Japanese version, visit www.iqvia.co.jp.

About Japanese Foundation for Cancer Research (JFCR)

Since its founding in 1908 as Japan's first specialized cancer research institute, the Japanese Foundation for Cancer Research has upheld the basic philosophy of "contributing to the welfare of humanity through overcoming cancer," and the institute and hospital have worked together to clarify the true nature and characteristics of cancer, contribute to the diagnosis, treatment, and prevention of cancer, and pioneer the cutting edge of life science. To achieve this, the JFCR actively conducts clinical trials for the development of new drugs, as well as clinical research that leads to the development of new treatments and diagnostic methods. The JFCR also promotes translational research, which links basic research to the development of diagnostic and treatment methods. (https://www.jfcr.or.jp/)

Contact Information

IQVIA Japan Group

Corporate Communications

Email: jp.coms@iqvia.com

Cancer Institute Hospital of Japanese Foundation for Cancer Research

Public Relations Division, Social Cooperation Department

Email: ganken-pr@jfcr.or.jp